CRE-Luc GPCR Reporter Mouse, Line 64

Random Transgenic

Live production of line 11518 will cease by May 23, 2018. Please contact Taconic for options if you have ongoing needs for this model.

FVB Background

  • Model #
  • Genotype
  • Nomenclature
  • 11518-F
  • 11518-M
  • Expresses luciferase under the control of the cAMP response element (CRE)
  • GPCR signaling through the cAMP pathway can be detected from the target GPCR that is in a native cellular environment with a full compliment of associated receptors and membrane constituents
  • Luciferase is expressed primarily in the spleen and kidney in Line 64
  • Useful for screening in vivo, ex vivo, and in vitro using whole animals, tissues and primary cells
  • Learn more about the CRE-Luc GPCR Reporter Mouse Platform
Orders by weight: Taconic cannot accept orders by weight for this model. Please note that shipments may contain animals with a larger weight variation.

Genetic Background:

FVB Background


The CRE-Luc GPCR Reporter Mouse, Line 64 was developed by Sanofi. The model was created by microinjecting a transgene containing a 6x CRE promoter, the HSV TK minimal promoter, modified firefly luciferase cDNA from pGL4 and a human growth hormone polyA tail. This transgene was microinjected into FVB/NTac zygotes. The resultant mice from founder line 64 were bred to FVB/NTac mice. Taconic received stock from Sanofi in 2012. The line was embryo transfer derived. In the production colony, the line is maintained by mating homozygous males and females.





Initial Publication:

Conditions of Use of Cre-Luc GPCR Mouse Model (‘Model”)
  • This Model is produced and distributed under rights to intellectual property, which are exclusively licensed to Taconic Biosciences, Inc. ("Taconic"). Taconic sells the Model to purchasers, and grants to each purchaser a right under Taconic's sublicensable rights in such intellectual property to use the purchased Model in consideration of purchaser's agreement to comply with Taconic's Terms and Conditions for the Sale of Products, and the following terms of use: Title to this Model and any biological materials (e.g. cells, nucleic acids, tissues, organs, antibodies, etc.) derived from them ("Biological Materials") remains with Taconic.
  • The Model will be used for research purposes only.
  • The Model will not be bred except to obtain embryos or fetuses required for research purposes (e.g., for obtaining embryonic neurons).
  • Purchasers may not (i) cross-breed the Model, (ii) genetically alter the Model or Biological Materials, and (iii) establish or maintain a culture of any Biological Materials (e.g., cell lines containing luciferase), with the exception of primary cells (e.g., neurons).
  • The Model and Biological Materials derived from it will not be distributed to third parties or used for commercial purposes.
  • Purchasers may not use this Model and/or Biological Materials derived from it in commercially sponsored research or contract research or contract research studies unless a separate Limited Use Agreement is signed.

Luciferase Animals Conditions of Use
Promega Corporation provides the following limited use license with respect to the luciferase gene (the "product") contained within the Cre-Luc Models. BY USE OF THE PRODUCT, RESEARCHER AGREES TO BE BOUND BY THE TERMS OF THIS LIMITED USE STATEMENT. If the researcher is not willing to accept the conditions of this limited use statement, and the product is unused, Taconic will accept written certification that the product was destroyed prior to use and will provide the researcher with a full refund. Researchers may use this product for research use only, no commercial use is allowed. Commercial Use means any and all uses of this product and derivatives by a party for monetary or other consideration and may include but is not limited to use in: (1) product manufacture; and (2) to provide a service, information or data; and/or resale of the product or its derivatives, whether or not such product or derivatives are resold for use in research. Researchers shall have no right to modify or otherwise create variations of the nucleotide sequence of the luciferase gene except that Researchers may: (1) create fused gene sequences provided that the coding sequence of the resulting luciferase gene has no more than four deoxynucleotides missing at the affected terminus compared to the intact luciferase gene sequence, and (2) insert and remove nucleic acid sequences in splicing research predicated on the inactivation or reconstitution of the luminescence of the encoded luciferase. No other use or transfer of this product or derivatives is authorized without the prior express written consent of Promega. In addition, Researchers must either: (1) use luminescent assay reagents purchased from Promega Corporation for all determinations of luminescence activity of this product and its derivatives; or (2) contact Promega Corporation to obtain a license for use of the product and its derivatives. Researchers may transfer derivatives to others for research use provided that at the time of transfer a copy of this label license is given to the recipients and recipients agree to be bound by the terms of this label license. With respect to any uses outside this label license, including any diagnostic, therapeutic or prophylactic uses, please contact Promega Corporation for supply and licensing information. PROMEGA MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED, INCLUDING FOR MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE WITH REGARDS TO THE PRODUCT. The terms of this license shall be governed under the laws of the State of Wisconsin, USA. The above license relates to Promega patents and/or patent applications on improvements to the luciferase gene.